- Home
- FCEL vs AVTX Comparison
FCEL vs AVTX Comparison
Compare FCEL & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCEL | AVTX |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 982.5M |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FCEL | AVTX |
|---|---|---|
| Price | $19.34 | $19.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $8.31 | ★ $40.57 |
| AVG Volume (30 Days) | ★ 8.5M | 729.8K |
| Earning Date | 06-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.24 | ★ 72.07 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $89,437,000.00 | $27,813,137.00 |
| Revenue This Year | $4.77 | N/A |
| Revenue Next Year | $42.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $3.81 | $8.65 |
| 52 Week High | $37.88 | $24.27 |
Technical Indicators
Market Signals| Indicator | FCEL | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 55.53 |
| Support Level | $17.33 | $17.40 |
| Resistance Level | $26.16 | $20.68 |
| Average True Range (ATR) | 2.28 | 1.06 |
| MACD | -0.14 | 0.04 |
| Stochastic Oscillator | 22.83 | 66.12 |
Price Performance
Historical ComparisonAbout FCEL FuelCell Energy Inc.
FuelCell Energy Inc is a clean energy technology company engaged in the development, design, production, and servicing of high temperature fuel cells for clean electric power generation. The Company provides proprietary molten carbonate fuel cell systems that generate electricity electrochemically with ultra low emissions and high efficiency, and operates as a solutions provider managing the design, manufacturing, installation, and maintenance of its systems under long term power purchase, service, and engineering procurement agreements. The Company serves utilities, data centers, and commercial and industrial customers, and operates in the United States, South Korea, Europe, and Canada, with maximum revenue generated from the United States.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.